Extramedullary plasma cell tumor (EMP) is a kind of plasma cell tumor, and its pathogenesis is not completely clear. According to whether it is independent of myeloma disease, it can be divided into primary and secondary EMP, which have different biological and clinical characteristics. Primary EMP has low invasion, fewer cytogenetic and molecular genetic abnormalities and good prognosis, and surgery and / or radiotherapy are the mainly treatments. Secondary EMP, as the extramedullary invasive progression of multiple myeloma (MM), is often accompanied by high-risk cellular and molecular genetic abnormalities and poor prognosis, chemotherapy, immunotherapy and hematopoietic stem cell transplantation are the mainly treatment. This paper reviews the latest research progress of EMP in the pathogenesis, cytogenetics molecular genetics and treatment, so as to provide reference for clinical work.
题目: 髓外浆细胞瘤的最新研究进展.
摘要: 髓外浆细胞瘤（EMP）属于浆细胞肿瘤的一种，其发病机制尚未完全明确，按照是否独立于骨髓瘤疾病发生可分为原发性和继发性EMP，两者具有不同的生物学和临床特征，原发性EMP侵袭度低，其细胞遗传学异常较少、预后良好，治疗多以手术和/或放疗为主；而继发性EMP作为多发性骨髓瘤（MM）的髓外侵袭性进展，常伴有高危细胞遗传学异常、预后较差，治疗以化疗、免疫治疗及造血干细胞移植等为主。本文从发病机制、细胞和分子遗传学、治疗等方面对EMP的最新研究进展进行综述，以期为临床工作提供参考。.
Keywords: extramedullary plasmacytoma; extramedullary lesions; multiple myeloma.